Phase IIa Dose Escalation Trial of NanoPac Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Nanology
- 26 Nov 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 15 Aug 2018 Planned End Date changed from 1 May 2018 to 1 Oct 2018.